<SEC-DOCUMENT>0001104659-25-004901.txt : 20250605
<SEC-HEADER>0001104659-25-004901.hdr.sgml : 20250605
<ACCEPTANCE-DATETIME>20250121161705
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001104659-25-004901
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250121

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Theriva Biologics, Inc.
		CENTRAL INDEX KEY:			0000894158
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				133808303
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		(734) 332-7800

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Synthetic Biologics, Inc.
		DATE OF NAME CHANGE:	20120305

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADEONA PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20081027

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PIPEX PHARMACEUTICALS, INC.
		DATE OF NAME CHANGE:	20061214
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_001.jpg" ALT="Theriva Biologics Inc.: Theriva ..." STYLE="height: 163px; width: 310px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right; text-indent: 30.05pt">January 21,
2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 5.4pt; text-align: right; text-indent: 30.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I><U>VIA EDGAR</U></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission<BR>
Division of Corporation Finance<BR>
100 F Street, N.E.<BR>
Washington, D.C. 20549<BR>
Attention: Tamika Sheppard</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 7%">Re:</TD><TD STYLE="width: 93%">Theriva Biologics, Inc.<BR>
Registration Statement on Form S-1<BR>
Filed December&nbsp;10, 2024, as amended<BR>
File No: 333-283722</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Ms. Sheppard:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Theriva Biologics, Inc. (the &ldquo;<B>Registrant</B>&rdquo;) hereby
requests that the effective date of the above-referenced Registration Statement on Form S-1 (File No. 333-283722), as amended, be accelerated
by the U.S. Securities and Exchange Commission (the &ldquo;<B>Commission</B>&rdquo;) to become effective on <B>Thursday, January 23, 2025</B>,
at <B>5:00 p.m</B>., Eastern Time, or as soon as reasonably practicable thereafter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant understands that the Staff of the Commission will consider
this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate
to the issuance of the securities covered by the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Registrant hereby authorizes Leslie Marlow of Blank Rome LLP to
orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (516) 457-4238 with any questions you may have concerning
this request, and please notify her when this request for acceleration has been granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">Very truly yours,</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 50%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 40%">&nbsp;</TD>
  <TD STYLE="width: 5%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">THERIVA BIOLOGICS, INC.</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
  <TD STYLE="padding-bottom: 1pt">By:</TD>
  <TD STYLE="border-bottom: Black 1pt solid">/s/ Steven A. Shallcross</TD>
  <TD STYLE="padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Name:</TD>
  <TD>Steven A. Shallcross</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer and Chief Financial Officer</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">cc: Leslie Marlow, Blank Rome LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "C 38# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M445Q!<9\F:.3'78P./RJ6L"PHJ.6>& !II8XP> 78#/YT1313IOAD21<XRC
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M/<?J*]FHG3JNHU>+5CQ<%7A*DJ-[23>_4\ST;0=1UVY^SZ=;E\??<\(GU/\
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M>TT6"VN;EKJXB@"23L,&1@,$X]ZX\3&5-*+G=]4:TVGJE8^>/A?_ ,CWHG_
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MZ= (;6%8T[XZD^I/>K-%95L3.L]=NQMAL'2PZ]U:]PHHHKG.P**** "BBB@
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M%%%3.3F[LNG35./*@HHHJ#0**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
